Jounce Therapeutics, Inc. (NASDAQ:JNCE) Receives Consensus Rating of “Buy” from Brokerages

Jounce Therapeutics, Inc. (NASDAQ:JNCEGet Rating) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $18.00.

Several equities analysts recently weighed in on JNCE shares. StockNews.com assumed coverage on shares of Jounce Therapeutics in a report on Thursday, March 31st. They set a “sell” rating on the stock. Sumitomo Mitsui Financial Group assumed coverage on Jounce Therapeutics in a report on Wednesday, March 16th. They issued an “outperform” rating and a $17.00 price target for the company. Zacks Investment Research downgraded Jounce Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. Cowen upgraded Jounce Therapeutics from a “market perform” rating to an “outperform” rating in a report on Friday, February 4th. Finally, Raymond James upgraded Jounce Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $15.00 to $20.00 in a report on Friday.

Several institutional investors have recently made changes to their positions in JNCE. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Jounce Therapeutics during the first quarter valued at about $26,000. Royal Bank of Canada lifted its position in shares of Jounce Therapeutics by 77.2% during the third quarter. Royal Bank of Canada now owns 4,533 shares of the company’s stock worth $34,000 after purchasing an additional 1,975 shares during the last quarter. Citigroup Inc. lifted its position in shares of Jounce Therapeutics by 36.3% during the third quarter. Citigroup Inc. now owns 6,369 shares of the company’s stock worth $47,000 after purchasing an additional 1,696 shares during the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Jounce Therapeutics by 184.8% during the third quarter. BNP Paribas Arbitrage SA now owns 9,406 shares of the company’s stock worth $70,000 after purchasing an additional 6,103 shares during the last quarter. Finally, Metropolitan Life Insurance Co NY bought a new position in shares of Jounce Therapeutics during the third quarter worth about $71,000. Institutional investors own 78.20% of the company’s stock.

JNCE stock opened at $5.49 on Friday. The stock has a market capitalization of $283.69 million, a P/E ratio of -2.98 and a beta of 1.12. Jounce Therapeutics has a one year low of $4.78 and a one year high of $9.81. The company has a 50 day moving average price of $6.66 and a two-hundred day moving average price of $7.43.

Jounce Therapeutics (NASDAQ:JNCEGet Rating) last announced its quarterly earnings results on Thursday, May 5th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.15). During the same quarter in the prior year, the business posted ($0.58) EPS. On average, equities analysts anticipate that Jounce Therapeutics will post -1.91 earnings per share for the current year.

Jounce Therapeutics Company Profile (Get Rating)

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors.

Read More

Analyst Recommendations for Jounce Therapeutics (NASDAQ:JNCE)

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.